Positions

Selected Publications

Principal Investigator On

Investigator On

  • AHOD1822 -- AnOpen-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2020 - 2026
  • AADVL18P1 – An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation”,  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2021 - 2026
  • ALTE1631, A Randomized Web-Based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2019 - 2025
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2019 - 2025
  • Per Case Reimbursement COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2019 - 2025
  • Institutional Support NIH Pediatric Early Phase Clinical Trials Network (PEP-CTN) Grant (UM1CA228823) Successor To NIH Phase I Grant (2UM1CA097452)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2019 - 2025
  • Cookies for Kids' Cancer Phase 1 Supplemental  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2025
  • AHOD1331-A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2025
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2020 - 2025
  • AALL1931 - An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coll-Derived Asparaginases  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2019 - 2024
  • AALL 1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2- Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Lukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2024
  • ADVANCING ALSTATE (Alabama Lifespan Sickle cell Tracking Access Towards Equality) Network  awarded by CDC - Centers for Disease Control and Prevention/DHHS 2020 - 2023
  • Pediatric Early Phase Clinical Trial Network Grant (UM1CA228823) (PEPCTN)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2023
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2020 - 2023
  • AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin (NSC#772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+B-Acute Lymphoblastic Leukemia(B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2022
  • AHOD1721, Risk-based, Response-Adapted, Phase ll Open- Label Trail of Nivolumab+Brentuximab Vedotin(N+Bv) for Children,Adolescents, and Young Adults with Relapsed/ Refractory (R/R) CD30+ Classic Hodgkin Lymphoma (cHL) after Failure of First -Line Therapy, followed by Brentuximab+Bendamustine(Bv+B) for participants with a suboptimal response;CheckMate 744:Checkpoint Pathway and Nivolumab Clinical Trail Evaluation.  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2022
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2019 - 2022
  • Reduced Burden Of Oncology Therapy in Advanced B-Cell Lymphoma (REBOOT ABLY) in Children, Adolescents, and Young Adults with CD20+ Mature B-Cell Lymphoma  awarded by NEW YORK MEDICAL COLLEGE 2017 - 2022
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2018 - 2021
  • Project EveryChild APEC14B1  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2021
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2015 - 2021
  • Hyundai Hope on Wheels Impact Grant  awarded by HYUNDAI HOPE ON WHEELS 2018 - 2020
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2020
  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2020
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2020
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • Developing a Network to Utilize Administrative and Clinical Data for Childhood, Adolescent and Young Adult Oncology Survivorship Research  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP 2015 - 2018
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2018
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2018
  • A Phase 2 Multicenter, Single-Arm, Open-Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid®) in Pediatric Subjects from 1 To < 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2018
  • AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2018
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2013 - 2017
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2017
  • Novel Methods to Detect Gene-Environment Interactions in Treatment-Related Brain Tumors Among Childhood Cancer Survivors  awarded by University of Wisconsin-Milwaukee 2015 - 2016
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2015
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2015

    • Education And Training

  • Doctor of Medicine, University of Florida 2002
  • MassGeneral Hospital for Children, Internship 2003
  • Masachusetts General Hospital, Residency 2005
  • Children's Hospital Los Angeles, Postdoctoral Fellowship 2009

    • Full Name

  • Julie Wolfson-Stockman